About Standigm
Standigm is a biotechnology company specializing in artificial intelligence-powered drug discovery and development. Founded to address the inefficiencies and high costs of traditional drug discovery, Standigm has developed proprietary AI platforms that integrate deep learning, machine learning, and biological knowledge to identify novel drug candidates, predict drug efficacy, and discover new therapeutic targets. The company's technology analyzes vast amounts of biomedical data including genomics, proteomics, and chemical structures to uncover hidden relationships between diseases, targets, and compounds. Standigm serves pharmaceutical companies, biotechnology firms, and academic research institutions seeking to accelerate their drug discovery pipelines and reduce development costs. The platform has demonstrated capabilities across multiple therapeutic areas including oncology, metabolic diseases, and rare diseases. By combining computational predictions with experimental validation, Standigm aims to increase the success rate of drug development while significantly reducing the time and cost required to bring new therapeutics to market. The company represents a new generation of AI-native biotech firms transforming how medicines are discovered and developed.
Clinical Focus
Medical conditions and clinical areas addressed by Standigm.
Who It Serves
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.